This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dubois, V. Articles by Trouet, A. Search for Related Content PubMed PubMed Citation Articles by Dubois, V. Articles by Trouet, A.

CPI-0004Na, a New Extracellularly Tumor-Activated Prodrug of Doxorubicin

In Vivo Toxicity, Activity, and Tissue Distribution Confirm Tumor Cell Selectivity¹

Université Catholique de Louvain, Laboratory of Cell Biology, Louvain-la-Neuve, Belgium [V. D., L. D., K. L., F. C., N. He., N. Ha., A-M. F., A. T.], and Corixa Corporation, South San Francisco, California 94080 [T. J. L., C. O., M. N., D. S., G. T. Y.]

The search for cancer therapies that are more selective for tumor cells andspare normal sensitive cells has been very active for at least 20 years. The extracellularly tumor-activated peptidic prodrug of doxorubicin (Dox) CPI-0004Na (N-succinyl-ß-alanyl-L-leucyl-L-alanyl-L-leucyl-Dox) is potentially such a treatment. Here, we report the results of lethality studies performed with this compound in the mouse, showing that it is up to 4.6 times less toxic than Dox·HCl by the i.v. route and up to 16.2 times after i.p. administration. Pharmacokinetics and tissue distribution data indicate that this reduced toxicity is attributable to a lower uptake of Dox in normal tissues after treatment with CPI-0004Na than after the administration of an equimolar dose of Dox·HCl. For example, heart exposure to Dox is reduced >10-fold. Because of this reduced toxicity, higher doses of CPI-0004Na than of the parent drug could be used to treat nude mice bearing s.c. human breast (MCF-7/6) and colon (LS-174-T and CXF-280/10) tumors. In all three models, the prodrug showed a much improved efficacy as compared with Dox·HCl. Particularly, LS-174-T tumors that do not respond to Dox were inhibited by 68% after treatment with CPI-0004Na. Tissue distribution studies performed with MCF-7/6 tumor-bearing nude mice and comparing CPI-0004Na and Dox·HCl confirmed that the improved activity of the prodrug is actually the result of selective generation and uptake of Dox at the tumor site. Dox levels in tumor tissue were 2-fold higher after treatment with CPI-0004Na than after treatment with an equimolar dose of Dox·HCl, whereas normal tissue levels were reduced 1.4–29-fold.

This article has been cited by other articles:

				D. Ravel, V. Dubois, J. Quinonero, F. Meyer-Losic, J. Delord, P. Rochaix, C. Nicolazzi, F. Ribes, C. Mazerolles, E. Assouly, et al. Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin Clin. Cancer Res., February 15, 2008; 14(4): 1258 - 1265. [Abstract] [Full Text] [PDF]

				W. Wu, Y. Luo, C. Sun, Y. Liu, P. Kuo, J. Varga, R. Xiang, R. Reisfeld, K. D. Janda, T. S. Edgington, et al. Targeting Cell-Impermeable Prodrug Activation to Tumor Microenvironment Eradicates Multiple Drug-Resistant Neoplasms Cancer Res., January 15, 2006; 66(2): 970 - 980. [Abstract] [Full Text] [PDF]

				C. F. Albright, N. Graciani, W. Han, E. Yue, R. Stein, Z. Lai, M. Diamond, R. Dowling, L. Grimminger, S.-Y. Zhang, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity Mol. Cancer Ther., May 1, 2005; 4(5): 751 - 760. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				G. L. Griffiths, M. J. Mattes, R. Stein, S. V. Govindan, I. D. Horak, H. J. Hansen, and D. M. Goldenberg Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate Clin. Cancer Res., December 15, 2003; 9(17): 6567 - 6571. [Abstract] [Full Text] [PDF]

				C. Pan, P. M. Cardarelli, M. H. Nieder, L. B. Pickford, S. Gangwar, D. J. King, G. T. Yarranton, D. Buckman, W. Roscoe, F. Zhou, et al. CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors Cancer Res., September 1, 2003; 63(17): 5526 - 5531. [Abstract] [Full Text] [PDF]

				A. M. Mansour, J. Drevs, N. Esser, F. M. Hamada, O. A. Badary, C. Unger, I. Fichtner, and F. Kratz A New Approach for the Treatment of Malignant Melanoma: Enhanced Antitumor Efficacy of an Albumin-binding Doxorubicin Prodrug That Is Cleaved by Matrix Metalloproteinase 2 Cancer Res., July 15, 2003; 63(14): 4062 - 4066. [Abstract] [Full Text] [PDF]